Overview of Treatment Approaches for Fungal Infections
Invasive fungal diseases cause high morbidity and mortality in an immunocompromised host. Antifungals are the drugs of choice and can be divided into 4 main groups: polyenes, azoles, echinocandins, and pyrimidine analogues. Each class has its specific mechanism of action, spectrum of activity, and p...
Saved in:
| Published in | Clinics in chest medicine Vol. 38; no. 3; p. 393 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | English |
| Published |
United States
01.09.2017
|
| Subjects | |
| Online Access | Get more information |
Cover
Loading…
| Abstract | Invasive fungal diseases cause high morbidity and mortality in an immunocompromised host. Antifungals are the drugs of choice and can be divided into 4 main groups: polyenes, azoles, echinocandins, and pyrimidine analogues. Each class has its specific mechanism of action, spectrum of activity, and pharmacokinetic and side effects. It is important to understand the precise use of the established and new antifungal agents to successfully manage these complex infections in an already tenuous and frail host. This article discusses the main characteristics, clinical uses, and secondary effects of the main antifungals used in clinical practice. |
|---|---|
| AbstractList | Invasive fungal diseases cause high morbidity and mortality in an immunocompromised host. Antifungals are the drugs of choice and can be divided into 4 main groups: polyenes, azoles, echinocandins, and pyrimidine analogues. Each class has its specific mechanism of action, spectrum of activity, and pharmacokinetic and side effects. It is important to understand the precise use of the established and new antifungal agents to successfully manage these complex infections in an already tenuous and frail host. This article discusses the main characteristics, clinical uses, and secondary effects of the main antifungals used in clinical practice. |
| Author | Limper, Andrew H Carmona, Eva M |
| Author_xml | – sequence: 1 givenname: Eva M surname: Carmona fullname: Carmona, Eva M email: carmona.eva@mayo.edu organization: Thoracic Diseases Research Unit, Division of Pulmonary Critical Care and Internal Medicine, Department of Medicine, Mayo Clinic, Mayo Foundation, 200, 1st Street Southwest, Rochester, MN 55905, USA. Electronic address: carmona.eva@mayo.edu – sequence: 2 givenname: Andrew H surname: Limper fullname: Limper, Andrew H organization: Thoracic Diseases Research Unit, Division of Pulmonary Critical Care and Internal Medicine, Department of Medicine, Mayo Clinic, Mayo Foundation, 200, 1st Street Southwest, Rochester, MN 55905, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28797484$$D View this record in MEDLINE/PubMed |
| BookMark | eNo1z7tOwzAUgGELgeiNB2BBfoGEcxxfkrGqaKlUqUuZK9s5LqkaJ3LSIt6eAZj-7ZP-GbuPXSTGnhFyBNSv59z7NheAJgeZAxR3bIpKmawUqCdsNgxnAFRQmUc2EaWpjCzllOn9jdKtoS_eBX5IZMeW4siXfZ866z9p4KFLfH2NJ3vh2xjIj00XhwV7CPYy0NNf5-xj_XZYvWe7_Wa7Wu4yL6EcM4NOiopCEHVN2jsjnC61I6nQKVJUe1tpoUXhKtSFcGhIS-8huKK2qghizl5-3f7qWqqPfWpam76P_wPiB7zfSMA |
| CitedBy_id | crossref_primary_10_3390_nano12010051 crossref_primary_10_1007_s42770_024_01295_0 crossref_primary_10_3390_app9040786 crossref_primary_10_22159_ijcpr_2022v14i5_2030 crossref_primary_10_2217_fmb_2022_0269 crossref_primary_10_3390_antibiotics12030608 crossref_primary_10_3390_app11157119 crossref_primary_10_1016_j_crgsc_2021_100138 crossref_primary_10_3389_fcimb_2020_00463 crossref_primary_10_4236_ijcm_2018_99054 crossref_primary_10_29328_journal_adr_1001019 crossref_primary_10_1016_j_ejmech_2018_05_001 crossref_primary_10_1002_ardp_202200266 crossref_primary_10_2174_0118715265266257231022134933 crossref_primary_10_1016_j_ejmech_2019_05_047 crossref_primary_10_3389_fmicb_2022_1061603 crossref_primary_10_1016_j_ejmech_2019_111689 crossref_primary_10_1016_j_micres_2023_127517 crossref_primary_10_1016_j_ejmech_2021_113987 crossref_primary_10_1371_journal_pntd_0007441 crossref_primary_10_2174_1389450123666220623164548 crossref_primary_10_1080_17425255_2020_1764939 crossref_primary_10_1093_jac_dkaa515 crossref_primary_10_3390_metabo10030106 crossref_primary_10_1007_s11274_024_03916_0 crossref_primary_10_1016_j_chom_2023_12_012 crossref_primary_10_1021_acsmedchemlett_3c00463 crossref_primary_10_1016_j_bioorg_2020_104248 crossref_primary_10_1016_j_sciaf_2024_e02292 crossref_primary_10_1186_s12879_018_3333_0 crossref_primary_10_1021_acs_jmedchem_1c01991 crossref_primary_10_3139_113_110667 crossref_primary_10_1111_apm_13389 crossref_primary_10_1021_acs_jmedchem_7b01138 crossref_primary_10_3897_pharmacia_70_e111511 crossref_primary_10_3390_antibiotics12030509 crossref_primary_10_3390_ph15020212 crossref_primary_10_3390_antibiotics9090568 crossref_primary_10_1016_j_rechem_2022_100721 crossref_primary_10_3390_jof8050442 crossref_primary_10_2174_2210303109666190508082009 crossref_primary_10_2217_fmb_2019_0173 crossref_primary_10_1002_cmdc_202100577 crossref_primary_10_1007_s10238_022_00935_9 crossref_primary_10_3390_microorganisms8101574 crossref_primary_10_1016_j_ejmech_2022_114195 crossref_primary_10_1016_j_mycmed_2018_06_008 crossref_primary_10_1016_j_fgb_2017_11_008 crossref_primary_10_1093_mmy_myz012 crossref_primary_10_2174_1570180815666180326152726 crossref_primary_10_1016_j_ejmech_2021_113955 crossref_primary_10_1016_j_ccr_2023_215608 crossref_primary_10_1016_j_ejmech_2021_113715 crossref_primary_10_2217_fmb_2022_0224 |
| ContentType | Journal Article |
| Copyright | Copyright © 2017 Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: Copyright © 2017 Elsevier Inc. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM |
| DOI | 10.1016/j.ccm.2017.04.003 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
| DatabaseTitleList | MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1557-8216 |
| ExternalDocumentID | 28797484 |
| Genre | Journal Article Review |
| GroupedDBID | --- .1- .FO .GJ 0R~ 123 1KJ 1P~ 29B 34G 39C 4.4 457 53G 5RE 6J9 6PF AAEDT AAEDW AALRI AAQQT AAQXK AAWTL AAXUO ABCQX ABFRF ABJNI ABMAC ABQZK ACGFO ADBBV ADMUD AEFWE AENEX AEVXI AFCTW AFFNX AFRHN AFTJW AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ ASPBG AVWKF AXIYT AZFZN B08 CGR COIAO CUY CVF DAHGL DU5 EBS ECM EIF EJD EX3 F5P FDB FEDTE FGOYB HVGLF HZ~ L7B N4W NPM O9- OI- OU. P2P R2- RIG SEL SES UNMZH WOW Z5R ZGI |
| ID | FETCH-LOGICAL-c408t-71b429eff2dde6cb72b686be451b5e5edca962623b91632b17e64cc0fb3da53f2 |
| IngestDate | Wed Oct 16 01:00:11 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Antifungal Amphotericin Triazoles Echinocandins Flucytosine Fungal infections Invasive mycoses |
| Language | English |
| License | Copyright © 2017 Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c408t-71b429eff2dde6cb72b686be451b5e5edca962623b91632b17e64cc0fb3da53f2 |
| PMID | 28797484 |
| ParticipantIDs | pubmed_primary_28797484 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-09-01 |
| PublicationDateYYYYMMDD | 2017-09-01 |
| PublicationDate_xml | – month: 09 year: 2017 text: 2017-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinics in chest medicine |
| PublicationTitleAlternate | Clin Chest Med |
| PublicationYear | 2017 |
| SSID | ssj0015097 |
| Score | 2.448537 |
| SecondaryResourceType | review_article |
| Snippet | Invasive fungal diseases cause high morbidity and mortality in an immunocompromised host. Antifungals are the drugs of choice and can be divided into 4 main... |
| SourceID | pubmed |
| SourceType | Index Database |
| StartPage | 393 |
| SubjectTerms | Antifungal Agents - therapeutic use Humans Mycoses - therapy |
| Title | Overview of Treatment Approaches for Fungal Infections |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/28797484 |
| Volume | 38 |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwFA5OQXwR73fJg2_S0SZtkj6O4Rji5ssGextNmoCCm4zhg7_ek0vXuSleXkpp2tLm6zn9zsm5IHRTCk1KAdaJFHkZpcSAHsyYjFTKC0I0Swyzycm9PusO0_tRNqo707nskrlsqvcv80r-gyocA1xtluwfkF3cFA7APuALW0AYtr_C-PHNSrrPPBksIsZboUy4dqUWbjsgzq6gho-6Ct65qjiBS4x0MbGuc9baWnu7mMHrOIYJpLv2nT48Ad-e1SGRIckh-A_gn1QFSIH6DzovA4CIT3mslCIVS-DTJQ1HfUPDNc3rnQDPTaVsfn_CXQHZ-NO5MHmvLw4KMNPyUMT0h9GVYtjVUAM1uLBqrW-dM2HRCLgPrxauXQjfyrPYws_h-hUjwpGJwR7aDVYAbnlI99GGnhyg7V6Y-0PEKmTx1OAFsrhGFgOy2COLa2SP0LBzN2h3o9DhAmQhFvOIJxL4gDaGwF-GKcmJZIJJnWaJzHSmS1XkYHESKoHFUyITrlmqVGwkLYuMGnKMNifTiT5FmLJCJnFRcOB4qVa2L2iclznPQeok4ekZOvFvPH71ZUzG1VycfztygXbqL-YSbRmQG30FJGwur93UfwAkky-L |
| link.rule.ids | 783 |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Overview+of+Treatment+Approaches+for+Fungal+Infections&rft.jtitle=Clinics+in+chest+medicine&rft.au=Carmona%2C+Eva+M&rft.au=Limper%2C+Andrew+H&rft.date=2017-09-01&rft.eissn=1557-8216&rft.volume=38&rft.issue=3&rft.spage=393&rft_id=info:doi/10.1016%2Fj.ccm.2017.04.003&rft_id=info%3Apmid%2F28797484&rft_id=info%3Apmid%2F28797484&rft.externalDocID=28797484 |